Key result
Oral verapamil SR significantly reduced platelet thrombus formation compared to baseline (3.1 vs 7.0 microns^2, P<0.05) in stable coronary patients.
Why the study?
Does oral verapamil reduce platelet thrombus formation and aggregation in stable coronary patients?
Population
18 stable coronary patients
Comparison
Oral verapamil SR for 7 days, and a combination… vs Baseline when receiving no active medications
Design
Cohort
Follow-up
7 days per treatment phase
Authors
Loading...
Verapamil SR was associated with reduced thrombus formation; hypothesis-generating and should not yet change practice in stable CAD.
Does oral verapamil reduce platelet thrombus formation and aggregation in stable coronary patients?
Absolute Event Rate: 3.1% vs 7%
p-value: p=<0.05
Oral verapamil significantly inhibits platelet thrombus formation and whole blood platelet aggregation in stable coronary patients, suggesting an antithrombotic benefit.
L-Lacoste et al. (1994) studied Stable coronary disease (n=18). Oral verapamil SR vs. Baseline (no active medications) was evaluated on Platelet thrombus formation (microns^2) (p=<0.05). Oral verapamil SR significantly reduced platelet thrombus formation compared to baseline (3.1 vs 7.0 microns^2, P<0.05) in stable coronary patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: